Pardos-Gea J, Barquinero J, Alvarez I, Cortina V, Garcia Martínez I, Martín Fernández L, Vidal F
A comprehensive review of the autoimmune pathogenesis of acquired hemophilia A.
Thromb Res . 2025 Oct:254:109444.
DOI: 10.1016/j.thromres.2025.109444.
IF: 3.4
RESEARCH GROUPS
Gene and Cell Therapy
1
Number of publications
0.00
%
% Q1
0.00
%
% D1
100.00
%
% Leadership
0.00
%
% Female Leadership
0.46
CROWN (2021-2025)
0.00
%
HCP10% (2021-2025)
0.00
%
% Open access
100.00
%
% International Collaboration
0
Highly cited papers / HCP 1% (2021-2025)
0
Publications in high-IF journals with high Altmetric scores
2
Number of Ongoing Projectes (total)
0
International ongoing projects
0
Number of New projects (total)
0
International new projects
0
Number of Active clinical Trials
0
Number of New Clinical Trials
0
Number of Theses
Over the past year, our group has been working on the search for and development of new strategies based on the transplantation of mesenchymal stem cells (fibroblasts and adipocytes) for the treatment of congenital muscular dystrophy due to merosin deficiency, as well as on gene editing techniques using these cell types as targets for potential ex vivo therapies. Furthermore, in collaboration with J. Verdaguer's group (University of Lleida), we have investigated the various biological activities and mechanisms of action of a family of peptides derived from intermediate filaments. In experiments conducted to date, these peptides have demonstrated potent immunostimulatory activity and transduction enhancement with retroviral vectors. Therefore, we are exploring the use of these peptides as adjuvants in cancer vaccines and as transduction enhancers in ex vivo gene therapy.
CORE/MISSIONS
- Innovative & Advanced Therapies
- Rare Diseases
PROGRAMS
TEAM
Group Leader
Jordi Barquinero Máñez
Researchers
Maria Pallarés Masmitjà
PhD Students
Rocío Piñera Moreno
Lab Technicians
Oscar Garriga Monterde
SELECTED PUBLICATIONS
SELECTED PROJECTS
Congenital muscular dystrophy type 1A: fibrosis inhibition and correction through gene editing.
Principal Investigator: Francina Munell and Jordi Barquinero
Agency: Instituto de Salud Carlos III
Funding: 117,370 €
Period: 2023-2025
Towards a gene therapy for MDC1A
Principal Investigator: Francina Munell and Jordi Barquinero
Agency: Ajuntament de Castellbisbal / Associació Impulsa't
Funding: 20,000 €
Period: 2025
National network on advanced therapies (TERAV+)
Principal Investigator: Manuel Juan (node UAB/VHIR: Miguel Chillon)
Agency: ISCIII. REDES DE INVESTIGACIÓN COOPERATIVA ORIENTADAS A RESULTADOS EN SALUD (RICORS). RD24/0014/0039
Funding: 140,239€
Period: 2025 - 2027
PATENTS
DISSEMINATION ACTIVITIES
Gene therapy for internists
Place: Vall d'Hebron Hospital
Date: 30/05/2025
Brief: Dissemination seminar
Publicactions officer at the Societat Catalana de Biologia.
Place: Societat Catalana de Biologia
Date: 2025
Brief: Coordination of all the publications of the Society, including the journal "Treballs de la Societat Catalana de Biologia" and the 2nd volume of "100 anys d'Història de la Societat Catalana de Biologia".
